title,url,date,category
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity,https://lilly.mediaroom.com/2024-12-20-FDA-approves-Zepbound-R-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-to-severe-obstructive-sleep-apnea-in-adults-with-obesity,2024-12-20,regulatory approval
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease,https://lilly.mediaroom.com/2024-12-17-Lillys-Kisunla-TM-donanemab-azbt-Approved-in-China-for-the-Treatment-of-Early-Symptomatic-Alzheimers-Disease,2024-12-17,regulatory approval
